PMV Pharmaceuticals(US:PMVP)2026-03-06 13:24Financial Performance - PMV Pharmaceuticals reported a net loss of $77.7 million for the year ended December 31, 2025, compared to a net loss of $58.7 million in 2024, representing a 32.4% increase in losses year-over-year[6][18]. - Total operating expenses for 2025 were $86.2 million, slightly up from $85.4 million in 2024[6][18]. - The company reported a weighted-average common shares outstanding of 52,541,613 for the year ended December 31, 2025, compared to 51,578,807 in 2024[18]. Research and Development - Research and development expenses increased to $69.9 million in 2025 from $58.5 million in 2024, primarily due to clinical expenses for advancing the lead product candidate, rezatapopt[6][18]. - The Phase 1 results of the ongoing PYNNACLE study demonstrated antitumor activity in heavily pretreated patients across multiple solid tumor types, supporting the efficacy of rezatapopt[5][8]. Clinical Trials - The ongoing PYNNACLE Phase 2 trial showed a 34% overall response rate among 103 evaluable patients, with a median duration of response of 7.6 months[8]. - In the ovarian cancer cohort of the PYNNACLE trial, a 46% overall response rate was observed among 48 evaluable patients, with a median duration of response of 8.0 months[8]. Regulatory Developments - The FDA granted Orphan Drug Designation to rezatapopt for the treatment of TP53 Y220C positive ovarian cancer, which may provide benefits such as market exclusivity for seven years if approved[5][8]. - PMV Pharma plans to submit a New Drug Application (NDA) for rezatapopt in platinum-resistant/refractory ovarian cancer in the first quarter of 2027[4][5]. Cash Position - As of December 31, 2025, the company had cash, cash equivalents, and marketable securities totaling $112.9 million, down from $183.3 million at the end of 2024, providing a cash runway expected to last until the end of the second quarter of 2027[4][6].